These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies. Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592 [TBL] [Abstract][Full Text] [Related]
24. The clinical significance of different hematopoietic stem cell sources (primed marrow, mobilized blood, and steady-state marrow) in autologous and allogenic transplantation. Chiang KY; Worthington-White D Exp Hematol; 2004 Aug; 32(8):698-9. PubMed ID: 15308319 [No Abstract] [Full Text] [Related]
25. Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation. MacDonald KP; Rowe V; Filippich C; Johnson D; Morris ES; Clouston AD; Ferrara JL; Hill GR Biol Blood Marrow Transplant; 2004 Jun; 10(6):373-85. PubMed ID: 15148491 [TBL] [Abstract][Full Text] [Related]
26. Peripheral blood stem cells for allogeneic transplantation. Russell NH; Hunter AE Bone Marrow Transplant; 1994 Apr; 13(4):353-5. PubMed ID: 7517257 [No Abstract] [Full Text] [Related]
27. Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. Bensinger WI; Buckner CD; Rowley S; Storb R; Appelbaum FR Bone Marrow Transplant; 1996 Mar; 17 Suppl 2():S19-21. PubMed ID: 8722328 [No Abstract] [Full Text] [Related]
28. Hematopoietic stem cell apheresis in the context of a related allogeneic transplant for acute myeloid leukemia: an unexpected outcome, medical emergency and ethical issue. Bourgeois M; Sonet A; Botson F; Graux C; Fabry A; André M; Deneys V Haematologica; 2017 Mar; 102(3):e115-e116. PubMed ID: 27927773 [No Abstract] [Full Text] [Related]
29. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). Lieschke GJ; Burgess AW N Engl J Med; 1992 Jul; 327(1):28-35. PubMed ID: 1375975 [No Abstract] [Full Text] [Related]
30. Peripheral blood progenitor cell transplantation: clinical, practical, and economic considerations. Symposium held at the London Regional Cancer Centre, London, Ontario, Canada, November 1993. Smith AM; Keating A J Hematother; 1994; 3(4):331-48. PubMed ID: 7537609 [No Abstract] [Full Text] [Related]
31. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688 [TBL] [Abstract][Full Text] [Related]
32. Biological therapies in bone marrow transplantation. Kochupillai V Indian J Med Res; 1995 Apr; 101():129-33. PubMed ID: 7538493 [TBL] [Abstract][Full Text] [Related]
33. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Ageitos AG; Varney ML; Bierman PJ; Vose JM; Warkentin PI; Talmadge JE Bone Marrow Transplant; 1999 Jan; 23(1):63-9. PubMed ID: 10037052 [TBL] [Abstract][Full Text] [Related]
35. Developments in allogeneic peripheral blood progenitor cell transplantation. Russell NH; Gratwohl A; Schmitz N Br J Haematol; 1998 Dec; 103(3):594-600. PubMed ID: 9858206 [No Abstract] [Full Text] [Related]
36. [Stem cell transplantation--more than bone marrow transplantation]. Egeland T; Thorsby E Nord Med; 1995; 110(12):307-9. PubMed ID: 8524629 [TBL] [Abstract][Full Text] [Related]
37. Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial. Wan L; Zhang Y; Lai Y; Jiang M; Song Y; Zhou J; Zhang Z; Duan X; Fu Y; Liao L; Wang C J Clin Oncol; 2015 Dec; 33(34):3999-4006. PubMed ID: 26392095 [TBL] [Abstract][Full Text] [Related]
38. Policies and procedures for the establishment of an allogeneic blood stem cell collection programme. Stroncek D; McCullough J Transfus Med; 1997 Jun; 7(2):77-87. PubMed ID: 9195692 [No Abstract] [Full Text] [Related]